Free Trial
NASDAQ:SRZN

Surrozen Q1 2025 Earnings Report

Surrozen logo
$8.35 -0.34 (-3.91%)
As of 05/9/2025 03:59 PM Eastern

Surrozen EPS Results

Actual EPS
-$3.13
Consensus EPS
-$1.09
Beat/Miss
Missed by -$2.04
One Year Ago EPS
N/A

Surrozen Revenue Results

Actual Revenue
$0.98 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Surrozen Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
12:30PM ET

Upcoming Earnings

Surrozen's Q2 2025 earnings is scheduled for Wednesday, May 14, 2025

Surrozen Earnings Headlines

100-year-old investment secret predicts what?!
Did you know? There's a strange investment secret discovered just before the Great Depression … That accurately called all the major financial events in recent history …
Surrozen files to sell 5.21M shares of common stock for holders
Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN), a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

View Surrozen Profile

More Earnings Resources from MarketBeat